1. Scrip
  2. >>R&D
  3. >>Clinical Trials

BMS SCLC Chances Dive After Opdivo, Yervoy Combo Flunks Checkmate-451

 
• By Sten Stovall

BMS's Phase III Checkmate-451 combo trial with Opdivo and Yervoy misses its endpoint for small cell lung cancer in overall survival, building on recent disappointment caused by the failure of Checkmate-331.

Lung cancer
Bristol-Myers Squibb's Checkmate-451 Tested Opdivo and Yervoy in Small cell Lung Cancer • Source: Shutterstock

Bristol-Myers Squibb Co.'s prospects in small cell lung cancer (SCLC) now look doubtful after the US group reported disappointing Phase III data from CheckMate-451 in which Opdivo (nivolumab) combined with Yervoy (ipilimumab) missed the primary endpoint of overall survival, analysts say.

The miss comes shortly after BMS's Phase III Checkmate-331 in relapsed small cell lung cancer using Opdivo failed to meet an overall survival endpoint compared to standard-of-care chemotherapy.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs

 
• By Alaric DeArment

Data from several closely watched solid tumor drug trials – some considered practice-changing – are scheduled for presentation at the meeting, including for AstraZeneca and Daiichi’s Enhertu.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.